首页> 外文OA文献 >Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

【2h】

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

机译：拉帕替尼加卡培他滨治疗HER-2阳性晚期乳腺癌的妇女：III期随机试验的最终生存分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The article presents final analyses of overall survival from a phase III trial of lapatinib and capecitabine in patients with human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer that progressed following prior therapy including trastuzumab.

机译：本文介绍了拉帕替尼和卡培他滨在人类表皮生长因子受体2阳性的局部晚期或转移性乳腺癌患者中进行的III期临床试验的总体存活率的最终分析，该患者在先前的治疗（包括曲妥珠单抗）后进展。

著录项

作者
Cameron, David; Casey, Michelle; Oliva, Cristina; Newstat, Beth; Imwalle, Bradley; Geyer, Charles E.;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 {"code":"en","name":"English","id":9}
中图分类

相似文献

外文文献
中文文献
专利

1. Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial [J] . Beth Newstat, Bradley Imwalle, Charles E. Geyer, The oncologist . 2010,第9期

机译：拉帕替尼加卡培他滨治疗HER-2阳性晚期乳腺癌的妇女：III期随机试验的最终生存分析
2. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. [J] . Cameron D, Casey M, Oliva C, The oncologist . 2010,第9期

机译：拉帕替尼加卡培他滨治疗HER-2阳性晚期乳腺癌的妇女：III期随机试验的最终生存分析。
3. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017) [J] . Dieras V, Miles D., Verma S. The lancet oncology . 2018,第12期

机译：Trastuzumab emtansine与Capecitabine Plus Lapatinib患者在先前治疗的Her2阳性晚期乳腺癌（艾米利亚）：对随机开放标签，第3阶段试验（Vol 18，PG 732,2017）的最终整体生存结果的描述性分析
4. META-ANALYSIS OF RANDOMIZED TRIALS OF TAMOXIFEN FOR EARLY BREAST CANCER [C] . V. ALBA-FERNANDEZ, J. MUNOZ-GARCIA Applied Simulation and Modelling . 2001

机译：他莫昔芬用于早期乳腺癌的随机试验的meta分析
5. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [D] . Wang, Ying. 2009

机译：在两个阶段的III期随机临床试验中比较评估生存概率的方法。
6. Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial [O] . David Cameron, Michelle Casey, Cristina Oliva, 2010

机译：拉帕替尼加卡培他滨治疗HER-2阳性晚期乳腺癌的妇女：III期随机试验的最终生存分析
7. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer:final survival analysis of a phase III randomized trial [O] . Cameron, David, Casey, Michelle, Oliva, Cristina, 2010

机译：Lapatinib联合卡培他滨治疗HER-2阳性晚期乳腺癌患者：III期随机试验的最终生存分析

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

摘要

著录项

相似文献

相关主题

期刊订阅